title: The role of topical immune response modifiers in skin cancer.
abstract: Topical immune response modifiers include imiquimod and resiquimod. The mechanism of action of immune response modifiers is complex and not completely understood. It involves the stimulation of innate and cell-mediated immune responses through Toll-like receptor-mediated induction of cytokines. Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget's disease.
authors.affiliation: University of Tennessee, Memphis, TN, USA.
authors.forename: Courtney
authors.initials: C
authors.lastname: Woodmansee
authors.forename: Jessica
authors.initials: J
authors.lastname: Pillow
authors.forename: Robert B
authors.initials: RB
authors.lastname: Skinner
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000077271:Imiquimod; D008954:Models, Biological; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D051193:Toll-Like Receptors / Q000502:physiology
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D016207:Cytokines; D007093:Imidazoles; D051193:Toll-Like Receptors; D000077271:Imiquimod; C402365:resiquimod